Showing 1 - 3 results of 3 for search 'Lersch, F', query time: 0.10s
Refine Results
-
1
Health-related quality of life (HRQoL) during treatment with enasidenib (ENA) plus azacitidine (AZA) in patients with newly diagnosed mutant IDH2 (m IDH2) acute myeloid leukemia (A... by DiNardo, CD, Dohner, H, Zeidan, AM, Schuh, AC, Vyas, P, Stein, EM, Wei, AH, de Botton, S, Chen, C, Lord-Bessen, J, Martin-Regueira, P, Lersch, F, Gong, J, Guo, S, Shi, L, Montesinos, P
Published 2021Conference item -
2
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, p... by DiNardo, CD, Schuh, AC, Stein, EM, Montesinos, P, Wei, AH, de Botton, S, Zeidan, AM, Fathi, AT, Kantarjian, HM, Bennett, JM, Frattini, MG, Martin-Regueira, P, Lersch, F, Gong, J, Hasan, M, Vyas, P, Döhner, H
Published 2021Journal article -
3
Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia by DiNardo, CD, Stein, AS, Stein, EM, Fathi, AT, Frankfurt, O, Schuh, AC, Döhner, H, Martinelli, G, Patel, PA, Raffoux, E, Tan, P, Zeidan, AM, de Botton, S, Kantarjian, HM, Stone, RM, Frattini, MG, Lersch, F, Gong, J, Gianolio, DA, Zhang, V, Franovic, A, Fan, B, Goldwasser, M, Daigle, S, Choe, S, Wu, B, Winkler, T, Vyas, P
Published 2020Journal article